Thryv Therapeutics Inc., a Canada-based privately owned company, announced on Tuesday that it has named Melissa Koomey M.B.A. as its new director.

Koomey has experience in product commercialisation, launch and marketing execution. She has more than 30 years of experience in product launch and marketing with global pharmaceutical companies across North America, including the last ten years in leadership positions at Gilead Sciences, Inc. She serves as vice president, Global Commercial Operations at Gilead Sciences (Nasdaq: GILD). She has held the position of vice president and general manager for Gilead Canada. She has also served in leadership positions across several therapeutic areas with FibroGen, Pfizer and Novartis.

Paul F Truex, Thryv's chairman and chief executive officer, said, 'We are excited to have Melissa join the Thryv board of directors at this pivotal time in our story. Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome. As our earlier portfolio in oncology advances to final stages of preclinical testing, Melissa's recent commercial launch experience will contribute to our path to commercialisation.'